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Abstract 
 
Operative removal of oncocytomas is generally unnecessary, but not infrequent in the 
context of renal masses. The infrequent use of pre-nephrectomy biopsies is a function of 
historical limitations of histopathological differential diagnosis in this setting. Assessment 
of clinicians’ receptiveness to a novel molecular diagnostic approach to this challenge was 
undertaken by means of a survey vehicle administered to 102 practicing urologists and 
pathologists who met inclusion criteria related to their actual clinical activity. Survey 
results supported the previously reported observations on misdiagnosis with urologists’ 
reported rates of 25% inconclusive results, and an additional 17% disagree with the final 
surgical diagnosis. The self-reported rate of 9% for pre-operative biopsies was comparable to 
prior reports, but 39% of urologists who are not currently performing pre-operative biopsies 
expressed interest in introducing them into their practice for this purpose with an improved 
diagnostic. Almost all urologists (94%) felt it important not to resect benign oncocytomas 
and 62% indicated they would use a test which improved the ability to sub-type renal 
tumors pre-operatively. The level of performance benchmark of the unidentified prototypic 
microRNA-based diagnostic as reported previously in the literature was deemed sufficient to 
change care in these cases by 73%. Overall they predicted a 38% rate of biopsies and 
resulting increases in decisions to forgo nephrectomy or to perform only partial 
nephrectomy. Pathologists also expressed support for the use of this technology in the 
context of inadequate specimens and for improved sub-typing of these tumors in 
inconclusive cases. Copyright: The Authors. 
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Introduction 
 
 
Renal cell carcinomas (RCC) are a family of 
carcinomas that arise from the epithelium 
of the renal tubules, and account for more 
than 3% of adult malignancies. The 
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estimated number of new U.S. cases has 
reached over 65,000 in recent years, and is 
the cause of death for over 13,000 annually 
(1-5). The incidence of RCC has increased 
significantly in recent years (2), likely due 
to a higher rate of incidental findings on 
abdominal imaging studies done for 
nonspecific abdominal complaints. RCC is 
characterized by a lack of early warning 
signs, diverse clinical manifestations, and 
tumor resistance to radiation and 
traditional chemotherapy. The 
longstanding mainstay of treatment is 
radical nephrectomy, however subtotal 
nephrectomy is being increasingly 
employed in part due to the identification 
of smaller tumors earlier in their course by 
imaging (5,6). 
Renal Oncocytoma (RO) is the most 
common benign tumor of the kidney, and is 
often misdiagnosed as RCC because of 
similar radiological and histological 
appearance. In particular, the 
Chromophobe RCC (chRCC) subtype may 
be challenging to discriminate from 
oncocytomas histopathologically. Three 
recent review articles (7-9) conclude that to 
date, histochemical, IHC, and genetic 
features have not proven to be reliable and 
specific enough markers for differential 
diagnosis of chRCC versus RO. 
ChRCC has many biological similarities to 
oncocytomas and both seem to have a 
different origin than papillary and clear cell 
(aka conventional) RCCs. While 
chromophobe cancers may have a 
somewhat more favorable prognosis than 
the other RCC subtypes, they are 
nonetheless malignant tumors with the 
potential for metastasis and death. 
Oncocytomas have now been consistently 
classified as benign, and appropriate for 
conservative management, with monitoring 
and expectant treatment rather than total 
nephrectomy. Only a single case report of 
metastases from ROs remains confirmed in 
the literature, with the absence of other 
cases strongly supporting this conservative 
approach (7). 
Imaging characteristics, including tumor 
size, alone has historically been a major 
factor in pre-operative diagnostic 
assessment to predict likelihood that a 
renal mass is malignant, but no imaging 
approach has been sufficient to adequately 
and fully differentiate these masses.  In 
fact, increased detection of smaller tumors 
incidentally is creating confusion and 
adding to the difficulty in presenting 
options to patients regarding intervention. 
In addition, some small renal masses found 
to be chRCCs today may, in some 
situations, be suitable for active 
surveillance similar to ROs rather than 
immediate resection or ablation (8). 
A recent study (6) showed that 
approximately 20% of nephrectomies 
performed for presumed RCC were in fact 
ROs on post-operative pathological 
evaluation, which remains consistent with 
past series cited. This is attributed at least 
in part to the fact that less than 10% of 
patients undergo a pre-operative diagnostic 
biopsy prior to having a nephrectomy for a 
presumed renal cancer (6). These low rates 
of pre-operative biopsy are largely 
attributed to less than desirable diagnostic 
accuracy by histology and 
immunohistochemistry in this setting (9, 
10).  
MicroRNAs are small non-coding RNA 
molecules that play an important role in 
the regulation of gene expression (11-13), 
which have been increasingly established 
as strong molecular biomarkers for clinical 
diagnostics (14-19). The tissue-specificity of 
microRNA expression opens a window to 
new types of molecular diagnostic assays, 
and its utility in kidney cancer 
classification and diagnosis has recently 
been described (20-22). A clinically 
validated microRNA-based diagnostic is 
now commercially available which 
discriminates accurately between the four 
most common kidney tumors, notably 
differentiating benign oncocytomas from 
chromophobe, papillary, and clear cell 
RCCs (22).  
In order to understand the perceived 
unmet need, clinical utility, and projected 
use of an improved diagnostic for pre-
operative decision making with kidney 
tumors, an independent third-party survey 
was conducted with practicing urologists 
and pathologists. The study’s intent was to 
explore the factors that influence testing for 
histological subtype in kidney cancer, the 
perceived accuracy of testing, and its
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    Table 1. Projected performance characteristics of diagnostic. 
Class 
% 
cases 
Sensitivity Specificity PPV NPV 
Clear (malignant) 73.0 98.15 99.20 99.8 95.2 
Papillary 
(malignant) 
15.7 98.04 99.25 91.9 99.6 
Chromophobe 
(malignant) 
5.2 92.86 96.50 83.3 99.6 
Oncocytoma 
(benign) 
6.1 86.50 98.00 93.4 99.1 
 
                         Table 2. Characteristics of Survey Participants. 
                        
impact on the decision to perform a 
resection. Premised upon the reported 
performance characteristics of a novel 
clinical microRNA based assay for 
subtyping of kidney tumors (Table 1), and 
urologists’ and pathologists’ current clinical 
practices, we explored their perceptions on 
integrating such a diagnostic tool into 
clinical practice, and identifying what 
significance such implementation may have 
on their decision to perform surgery and 
implications this may have on healthcare 
system costs. 
Methods 
MedPanel, LLC (Cambridge, MA, USA) is a 
research organization with an extensive 
global community of healthcare 
professionals across multiple clinical 
disciplines within both the community and 
academic medical center settings. 
MedPanel was commissioned to develop a 
survey to understand the perceived needs 
for better diagnosis in renal tumors and the 
potential impact of a new biomarker test 
with specified performance characteristics. 
(Supplementary files). It was a double-
blinded study whereby the participating 
physicians were blinded throughout the 
research as to the identity and source of 
this specific test, as well as the study 
sponsor’s identity, and the identity of the 
participants was confidential to the 
sponsor. 
The test performance profiled was shown 
as reported in recent publications for the 
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Figure 1. Frequency of use of pre-nephrectomy diagnostics in U.S. today. 
 
 
Figure 2. Performance of pre-operative biopsy histopathology. 
 
Rosetta Kidney Test™ (Table 1) based on a 
blinded validation of the assay in 201 
independent samples (22).  
Additional information was provided that 
overall, as to the test’s ability to 
discriminate “Malignant” vs “Benign”, the 
sensitivity for malignant was 98% with a 
specificity of 86.5%, and the turn-around-
time for results was approximately 7-10 
days (Supplementary Files). 
Practicing community and academic 
urologists and pathologists were recruited 
nationwide to participate in this survey. 
Criteria for study inclusion was that 
physicians be U.S. based board-certified 
urologists or pathologists experienced in 
the diagnosis and treatment of kidney 
cancer in clinical practice and have over 3 
but less than 30 years in practice. 
Urologists were required to be engaged in 
clinical practice at least 70% of their 
professional time, and manage a minimum 
of 5 kidney cancer patients per month. 
Pathologists were required to be engaged in 
performing clinical duties at least 30% of 
their professional time, and examine at 
least 5 biopsies per day. 
Participants completed a self-administered 
15-20 minute duration online survey 
tailored to their respective clinical 
discipline. The survey was fielded to over 
1,000 urologists and pathologists online 
from November 15 – 26, 2013 and had a 
total of 102 total respondents who met 
inclusion criteria of which 52 were 
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Figure 3. Factors that would make urologists more likely to biopsy. 
 
 
Figure 4. Current histological drivers of decision to resect kidney tumors. 
 
urologists and 50 were pathologists.  
Additionally, MedPanel conducted four 
hour long in-depth telephone interviews 
with US-based key opinion leading (KOL) 
caliber physicians or physician-scientists 
between October 21 – 28, 2013 to help 
inform the quantitative survey research 
and obtain further qualitative insights 
regarding interest in, and likely use of the 
test. Interviewees were required to have 
participated in clinical trials on emerging 
RCC therapies and to be capable of 
discussing trends in, and state of the art in 
kidney cancer diagnostics.  
Results  
The characteristics of the physicians 
participating in the survey are summarized 
in Table 2. Urologists participating spent 
an average of 95% of their time in clinical 
practice and has been practicing on 
average 17 years (Range: 5-30 years). They 
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Figure 5. Factors influencing decisions not to resect kidney tumors. 
 
 
Figure 6. Pathologists’ rationale for not performing pre-op sub-typing. 
 
saw a wide range of new kidney tumor 
cases annually (5-300), but on average, 62 
new cases were presented to them 
annually. On a monthly basis this 
represented between 5-85 unique patients 
managed on a monthly basis (Mean=23). 
The pathologist respondents had an 
average of 13 years in practice and 84% of 
their time was spent performing direct 
clinical duties. They examined an average 
of 25 primary tumor biopsies daily. Both 
clinician groups were spread across 
academic and community settings, with 
roughly equal numbers from the four 
quadrants of the U.S. geographically. The 
community hospital setting, as opposed to 
academic medical centers was represented 
slightly more for both types of practitioner. 
The majority of the time, CT scans are 
relied upon to diagnose patients with renal 
masses based on size and appearance, 
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Figure 7. Pathologist responses to inconclusive results. 
 
while pre-operative biopsies are used in 
less than 10% of cases (Figure 1). Only 1 
in 10 urologists routinely tests for 
histological subtype in pre-operative kidney 
tumors. Survey participants reported that 
they most often do not test for subtype 
because historically they have believed 
patients will require a resection regardless 
of subtype and/or the subtype will not 
change recommendation for resection. 
Histological subtype testing on pre-
operative kidney tumors is reported by 
respondents to be inconclusive in 25% of 
cases and not to match actual histology 
based on resection in an additional 17% of 
cases (Figure 2). Pathologists, on the other 
hand indicated that histology is 
inconclusive in only about 20% of cases. 
Additionally, 24% of pathologists concurred 
that there is a “great” need for more 
accurate histological testing for kidney 
tumors. They identified that among other 
factors, they would be most influenced to 
test pre-operatively for histological subtype 
prior to resection if testing was more 
accurate and/or it would substantively 
influence treatment decisions (Figure 3).  
The latter point is highlighted by the 
observation that when a tumor is known to 
be malignant, urologists would resect in 
over 90% of cases; and when the subtype is 
unknown or inconclusive, they would still 
resect 86% of the time. In contrast, when/if 
a tumor is diagnosed to be an oncocytoma, 
urologists report they prefer to watch and 
wait and would resect only 45% of such 
tumors (Figure 4). Patient wishes, and 
overall health and co-morbidities also 
factor in to decision-making regarding 
resection, but are largely influenced by 
tumor specific factors, most importantly, 
benign tumor type (21%) (Figure 5). 
In 8 out of 10 cases it is the pathologist 
who decides whether to test for subtype or 
not, or to do additional testing in the case 
of inconclusive results. Pathologists test for 
histological subtype in only half of pre-
operative kidney tumors compared to lung 
tumors. They are slightly more likely to 
present the clinician with a “best guess” 
answer when it comes to kidney histology 
compared to lung histology, for example. 
Although insufficient or inadequate tissue 
is the major limiting factor for not 
performing pre-operative sub-typing in the 
kidney setting, (Figure 6) pathologists also 
believe subtype is not as relevant to 
treatment decisions.  A small group of 
pathologists (6%) utilize genomic testing in 
this context to better define RCC. Overall, 
24% of pathologists indicated there is a 
“great” need for more accurate histological 
testing for kidney tumors, compared to 
52% who believe this for lung cancer.  
Among the 21% of cases reported to be 
inconclusive by pathologist respondents, 
just over half are referred to a second 
pathologist to evaluate the findings, and a 
second different histological test is 
performed in about 38% of cases (Figure 
7). About 30% of all samples are sent for 
ancillary testing; however, 26% of 
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Figure 8. Modifications to practice with increased knowledge. 
 
pathologists say the need to send samples 
out prevents them from using a secondary 
test. 
Treatment decisions today are clearly 
influenced by histological subtype, when 
known (Figure 4), and nearly universally, 
urologists (94%) believe it is important to 
avoid resecting a benign tumor. In untyped 
tumors later determined to be oncocytoma 
after resection, urologists would not have 
resected the tumor in 59% of cases if they 
had known the tumor was oncocytoma. 
Urologists stated they would use a tool that 
could more accurately classify tumor 
subtype in 62% of cases (Figure 8). 
After reviewing the aforementioned 
characteristics of the Rosetta Kidney 
Cancer TestTM, 73% of urologists think it 
provides meaningful enough results to 
change treatment of oncocytoma patients. 
They specifically expect cases where they 
would not perform a resection due to an 
oncocytoma diagnosis to jump from 59% to 
66%, and cases where they would perform 
a partial instead of a total nephrectomy to 
increase from 31% to 45%.  
Overall, 64% of pathologists believed the 
reported microRNA-based test performance 
to be superior to current testing sensitivity, 
and 58% believe it to be superior in terms 
of specificity. Pathologists believe sub-type 
testing pre-operatively could increase from 
50% to 62% of cases with availability of 
such a test. Somewhat more urologists 
(71%) believe the test’s performance is 
superior to current practice, and see 
sensitivity and specificity as most positive 
aspects of such a diagnostic.  
Urologists and pathologists tend to see this 
diagnostic used as a secondary test if the 
first was inconclusive. Urologists were 
more likely to suggest the use of the test as 
the primary test in pre-operative tumor 
cases (44%), than is projected by 
pathologists (23%) where most still expect 
to use the diagnostic if initial testing is 
inconclusive or upon clinician request.  
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Figure 9. Biopsy and medical-legal concerns minimal among Urologists. 
 
Urologists particularly noted the value of 
the diagnostic with high risk and/or 
comorbid patients.  
Surveyed physicians believe this test could 
increase testing of histological subtype as 
well as change treatment of oncocytoma 
patients. Urologists suggested that pre-
operative biopsy testing could increase 
from 10% to 38% of kidney tumor cases. 
The majority of urologists do not see the 
need to biopsy (67%) or medical-legal 
concerns (81%) as major barriers to use 
(Figure 9).  
When biopsies are done pre-operatively 
today they are roughly split between 
urologists (either primary or a referral) and 
interventional radiologists performing 
them. Among urologists not currently 
performing pre-operative biopsies, 39% 
expressed interest in performing them 
going forward prior to making a decision to 
resect (Figure 10).  
In examining urologists’ opinions on 
presented performance characteristics and 
test logistics (Figure 11), turnaround time 
and specimen requirements regarding 
volume and tumor cellular content are seen 
as the most negative aspects of the 
diagnostic as presented. Despite concerns 
regarding specimen content, pathologists 
believe there would be additional tissue left 
for testing with this diagnostic in 45% of 
cases. Moreover, without a specific 
prompting option, 10% of pathologists say 
they would use the diagnostic if a priori 
there is inadequate tissue for 
histopathological and IHC studies; 
suggesting the test’s requirements are for 
less tissue in total than current tests, and 
may yield a diagnosis in otherwise 
unreportable cases.  
Urologists’ perspectives on the costs and 
complication rates of biopsies versus total 
and partial nephrectomies are shown in 
Table 3, although the number of 
respondents in each group is sufficiently 
small for this to be considered only 
directional at most. 
Two out of four KOLs interviewed 
separately from the survey, believe the 
diagnostic would decrease the need to 
perform surgery; but as indicated by one 
KOL, this would entail a paradigm shift 
toward more pre-operative biopsies.  
Discussion  
Despite advanced imaging techniques and 
the availability of pre-operative renal 
biopsy, most surgical series continue to 
report significant rates of benign lesions 
among renal masses resected (6,8,23,24). 
Preoperative biopsy of kidney tumors is not 
widely employed (6-9) with only about 10% 
of all nephrectomies preceded by a 
diagnostic biopsy. This problem is 
longstanding, and despite 
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Figure 10. Pre-op kidney biopsy practitioners today and in the future. 
 
several academic center based studies 
suggesting adequate histopathological 
resolution is possible in this setting (25-
27), diagnostic uncertainty in the 
differentiation of benign RO from malignant 
chRCC (9,10) and in additional cases even 
with eosinophilic clear-cell RCCs (ccRCC) 
remains a clear contributing factor to low 
rates of biopsy in routine practice. Recent 
reviews by Ng et al. (8) and Yusenko (9,10) 
both concluded that there was no reliable 
diagnostic marker or IHC algorithm 
suitable for reliable differential diagnosis of 
renal tumors. Ng et al. (8) concluded as 
had Liu and Fanning (26), that there is a 
group of renal tumors, notably ROs and 
small chRCCs, where increased confidence 
in diagnosis would defer or totally eliminate 
the need for surgical intervention.  
The MedPanel survey reported here shows 
that practicing urologists and supporting 
pathologists in both academic and 
community settings across the United 
States, share the observations in the 
literature with their perceptions from their 
clinical practice. There is a similarly low 
rate of biopsy (9%) in our series and 
significant perception of inconclusive (25%) 
or inaccurate (17%) results from 
histopathological analysis of biopsies, 
resulting in a rate of oncocytomas in 
surgical series reasonably predictable to 
mirror that in the published literature.  
There was a strongly expressed need for 
improved diagnostic capabilities in the 
preoperative setting with kidney tumors. 
Urologists report that if the tumor type is 
known to be malignant, a total or partial 
nephrectomy is performed over 90% of the 
time, and similarly if the subtype is 
unknown, they did the same in 86% of 
cases, but perform nephrectomy only 45% 
of the time if the tumor is an oncocytoma. 
Overall, the tumor being benign plays a 
role in making a decision not to perform a 
resection 21% of the time today, which 
underlies the expressed unmet need here.  
The impact of this limitation of diagnostic 
capability was highlighted by a recent 
health economics outcome review of the 
management of kidney masses by Asnis-
Alibozek, et al (6). This study strongly 
supported the adverse economic and health 
outcomes impact of poor pre-operative 
diagnosis, and confirmed the reported very 
low rates of biopsy. In their analysis of the 
IMS LifeLink database covering over 60 
million commercially insured patients in 
the U.S., approximately 1 in 6 who 
underwent a nephrectomy for suspected 
RCC were subsequently identified as 
having benign disease with an economic 
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Figure 11. Test characteristics clinical favorability rankings. 
impact of approximately $26,500 per 
patient overall. This is in contrast to 
expenditures of approximately $1,300 total 
pre-operatively today, most commonly for 
one or more CT examinations. They 
projected that this represents over 10,000 
unnecessary surgeries in the United States 
alone annually.  
Complications after surgery, both acute 
and chronic are not uncommon, although 
slightly less frequent in patients with 
benign lesions versus malignant (17.5% 
versus 20% respectively) and result in 
expenditures of over $40,000 in the year 
following surgery. These include such 
serious results as acute and end-stage 
renal failure requiring dialysis and kidney 
transplant in some, and across the board, 
surgical overtreatment has a profound 
impact on patient health–related quality of 
life, and outcomes. This rate was 
substantially lower than the complication 
rate of 37% in surgically treated RCC 
patients cited by the authors from the 
SEER-Medicare database, however they 
noted the likelihood that the SEER-
Medicare data represented an older 
population with more co-morbidities (6). 
It is noteworthy that the urologists in the 
MedPanel survey on average under-
estimated the impact of nephrectomy in 
terms of costs and complication rates 
compared to the Asnis-Alibozek study, and 
by inference the SEER-Medicare population 
(Table 3). Thus the impact of the unmet 
need for better diagnosis identified by 
respondents is likely greater in these terms 
than the respondents appreciate (6).  
Patient comorbidities often play a role in 
the decision to not perform a resection, as 
indicated by 35% of urologists surveyed. In 
addition to avoiding the higher costs of 
surgery, better pre-operative discrimination 
of benign oncocytomas from RCCs would 
avoid significant morbidity from 
complications and potentially result in 
significantly lower related health care 
costs.  
Recent further clarity as to the 
appropriateness of watchful waiting in 
oncocytomas (28) today is likely to drive the 
number of patients who benefit from 
improved pre-operative diagnosis. Some 
residual hesitancy to manage ROs 
conservatively may remain due to the rare 
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Table 3. Procedural costs and complication rates. 
 Renal Biopsy Total Nephrectomy Partial Nephrectomy 
 Cost ($)  Complication 
Rate (%) 
Cost ($)  Complication 
Rate (%) 
Cost ($)  Complication 
Rate (%) 
Urologist 
Mean 
$1,222 
(N=9) 
5  
(N=29) 
$11,567 
(N=9) 
6  
(N=38) 
$7,200 
(N=8) 
11  
(N=37) 
Urologist 
Range 
$200-
$5,000 
0-20 
$100-
$40,000 
1-20 
$600-
20,000 
1-35 
AJMC 
2013 (8) 
ND ND 
$25,088 
20% ND ND 
 
reported cases of metastatic oncocytomas, 
however these cases may in fact represent 
misdiagnosed chRCCs, and better 
diagnosis would also improve this side of 
the equation. 
The purpose of our study was in part to 
assess the receptiveness of practicing 
clinicians to an alternative diagnostic 
paradigm that focuses on increased 
diagnostic accuracy. Avoiding unnecessary 
resections was clearly desirable, with 94% 
of urologists believing it is important to 
avoid resecting a benign kidney tumor. 
Histological subtype testing is known in 
only 1 out of 10 kidney tumors pre-
operatively and when the subtype is 
unknown or inconclusive, urologists resect 
86% of the time. In untyped tumors 
determined to be oncocytoma after 
resection, urologists would not have 
resected the tumor in 59% of cases if they 
had known the tumor was an oncocytoma.  
Ability to inform treatment decisions would 
drive use of more accurate diagnostic tests. 
Since the impact of diagnosis of benign 
oncocytomas clearly impacts treatment 
decisions, access to a more accurate test 
for histological subtype would increase the 
use of pre-nephrectomy biopsy of kidney 
tumors. Urologists and pathologists 
concurred that the published performance 
characteristics of microRNA-based profiling 
of kidney tumors is superior to existing 
technology and meets their criteria to 
increase testing of histological subtype 
preoperatively with resultant significant 
change in how they (73% of urologists 
surveyed) would treat oncocytoma patients. 
With the availability of this test, urologists 
would be almost four times more likely to 
check for subtype in pre-operative kidney 
tumors, and anticipate testing would 
increase from 10% to 38% of cases. 44% of 
urologists would use the Rosetta Kidney 
Cancer TestTM as a primary test for 
histological subtype, 56% would use it if a 
first test was inconclusive. With knowledge 
that a tumor is in fact an oncocytoma, 
cases where a resection would not be 
performed would increase from 59% to 66% 
and partial rather than total nephrectomies 
would go from 31% to 45%. 
In summary, urologists surveyed indicated 
that there is 1) a need for improved pre-
operative diagnosis; 2) the reported test 
meets their expectations in this regard; and 
3) they would act upon the results of this 
test to decrease the number of unnecessary 
surgeries. The literature supports that 
implementation of these three facets would 
result in lowered morbidity and overall 
healthcare expenditures related to kidney 
tumors. Better diagnostic certainty is 
essential to permit medical and surgical 
practices to evolve and improve. It is 
essential to integrate new tests, which 
enable reductions in unnecessary surgeries 
based on past standards of diagnostic 
certainty.  
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